FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2159392324> ?p ?o ?g. }

• W2159392324 endingPage "1268" @default.
• W2159392324 startingPage "1262" @default.
• W2159392324 abstract "Nootropic agents or cognitive enhancers are purported to improve mental functions such as cognition, memory, or attention. The aim of our study was to determine the effects of two possible cognitive enhancers, huperzine A and IDRA 21, in normal young adult monkeys performing a visual memory task of varying degrees of difficulty. Huperzine A is a reversible acetylcholinesterase (AChE) inhibitor, its administration results in regionally specific increases in acetylcholine levels in the brain. In human clinical trials, Huperzine A resulted in cognitive improvement in patients with mild to moderate form of Alzheimer’s disease (AD) showing its potential as a palliative agent in the treatment of AD. IDRA 21 is a positive allosteric modulator of glutamate AMPA receptors. It increases excitatory synaptic strength by attenuating rapid desensitization of AMPA receptors and may thus have beneficial therapeutic effects to ameliorate memory deficits in patients with cognitive impairments, including AD. The present study evaluated the effects of the two drugs in normal, intact, young adult monkeys to determine whether they can result in cognitive enhancement in a system that is presumably functioning optimally. Six young pigtail macaques (Macaca nemestrina) were trained on delayed non-matching-to-sample task, a measure of visual recognition memory, up to criterion of 90% correct responses on each of the four delays (10 s, 30 s, 60 s, and 90 s). They were then tested on two versions of the task: Task 1 included the four delays intermixed within a session and the monkeys performed it with the accuracy of 90%. Task 2 included, in each of 24 trials, a list of six objects presented in succession. Two objects from the list were then presented for choice paired with novel objects and following two of the four delays intermixed within a session. This task with a higher mnemonic demand yielded an average performance of 64% correct. Oral administration of huperzine A did not significantly affect the monkeys’ performance on either task. However, a significant negative correlation was found between the baseline performance on each delay and the change in performance under huperzine A, suggesting that under conditions in which the subjects were performing poorly (55–69%), the drug resulted in improved performance, whereas no improvement was obtained when the baseline was close to 90%. In fact, when the subjects were performing very well, huperzine A tended to reduce the performance accuracy, indicating that in a system that functions optimally, the increased availability of acetylcholine does not improve performance or memory, especially when the animals are close to the maximum performance. In contrast, oral administration of IDRA 21 significantly improved performance on Task 2, especially on the longest delay. This finding supports the potential use of this drug in treatment of cognitive and memory disorders. This article is part of a Special Issue entitled ‘Trends in Neuropharmacology: In Memory of Erminio Costa’." @default.
• W2159392324 created "2016-06-24" @default.
• W2159392324 creator A5026395120 @default.
• W2159392324 creator A5064494177 @default.
• W2159392324 creator A5083210265 @default.
• W2159392324 date "2011-06-01" @default.
• W2159392324 modified "2023-10-16" @default.
• W2159392324 title "The effects of huperzine A and IDRA 21 on visual recognition memory in young macaques" @default.
• W2159392324 cites W1982528995 @default.
• W2159392324 cites W1986541571 @default.
• W2159392324 cites W1988211095 @default.
• W2159392324 cites W1992294123 @default.
• W2159392324 cites W1993319593 @default.
• W2159392324 cites W1994997596 @default.
• W2159392324 cites W2003526387 @default.
• W2159392324 cites W2010359081 @default.
• W2159392324 cites W2011621207 @default.
• W2159392324 cites W2013975965 @default.
• W2159392324 cites W2016333532 @default.
• W2159392324 cites W2030008631 @default.
• W2159392324 cites W2030448540 @default.
• W2159392324 cites W2031079901 @default.
• W2159392324 cites W2035769972 @default.
• W2159392324 cites W2042318240 @default.
• W2159392324 cites W2050058512 @default.
• W2159392324 cites W2051942403 @default.
• W2159392324 cites W2054770298 @default.
• W2159392324 cites W2055328243 @default.
• W2159392324 cites W2058555776 @default.
• W2159392324 cites W2058881895 @default.
• W2159392324 cites W2059148941 @default.
• W2159392324 cites W2062856075 @default.
• W2159392324 cites W2062923618 @default.
• W2159392324 cites W2065305768 @default.
• W2159392324 cites W2065521724 @default.
• W2159392324 cites W2068498269 @default.
• W2159392324 cites W2078548800 @default.
• W2159392324 cites W2081803539 @default.
• W2159392324 cites W2086055820 @default.
• W2159392324 cites W2086557280 @default.
• W2159392324 cites W2087262968 @default.
• W2159392324 cites W2088289750 @default.
• W2159392324 cites W2104135708 @default.
• W2159392324 cites W2110315575 @default.
• W2159392324 cites W2118221604 @default.
• W2159392324 cites W2119396369 @default.
• W2159392324 cites W2145696702 @default.
• W2159392324 cites W2146766749 @default.
• W2159392324 cites W2149928573 @default.
• W2159392324 cites W2167933618 @default.
• W2159392324 cites W2168481396 @default.
• W2159392324 cites W2171779688 @default.
• W2159392324 cites W2952203187 @default.
• W2159392324 doi "https://doi.org/10.1016/j.neuropharm.2010.12.018" @default.
• W2159392324 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3073152" @default.
• W2159392324 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21185313" @default.
• W2159392324 hasPublicationYear "2011" @default.
• W2159392324 type Work @default.
• W2159392324 sameAs 2159392324 @default.
• W2159392324 citedByCount "15" @default.
• W2159392324 countsByYear W21593923242012 @default.
• W2159392324 countsByYear W21593923242014 @default.
• W2159392324 countsByYear W21593923242015 @default.
• W2159392324 countsByYear W21593923242016 @default.
• W2159392324 countsByYear W21593923242017 @default.
• W2159392324 countsByYear W21593923242018 @default.
• W2159392324 countsByYear W21593923242019 @default.
• W2159392324 countsByYear W21593923242022 @default.
• W2159392324 crossrefType "journal-article" @default.
• W2159392324 hasAuthorship W2159392324A5026395120 @default.
• W2159392324 hasAuthorship W2159392324A5064494177 @default.
• W2159392324 hasAuthorship W2159392324A5083210265 @default.
• W2159392324 hasBestOaLocation W21593923242 @default.
• W2159392324 hasConcept C126322002 @default.
• W2159392324 hasConcept C15744967 @default.
• W2159392324 hasConcept C160268369 @default.
• W2159392324 hasConcept C169760540 @default.
• W2159392324 hasConcept C169900460 @default.
• W2159392324 hasConcept C170493617 @default.
• W2159392324 hasConcept C181199279 @default.
• W2159392324 hasConcept C185592680 @default.
• W2159392324 hasConcept C185711340 @default.
• W2159392324 hasConcept C2776239663 @default.
• W2159392324 hasConcept C2776409846 @default.
• W2159392324 hasConcept C2778816929 @default.
• W2159392324 hasConcept C2779134260 @default.
• W2159392324 hasConcept C2779483572 @default.
• W2159392324 hasConcept C55493867 @default.
• W2159392324 hasConcept C61174792 @default.
• W2159392324 hasConcept C71924100 @default.
• W2159392324 hasConceptScore W2159392324C126322002 @default.
• W2159392324 hasConceptScore W2159392324C15744967 @default.
• W2159392324 hasConceptScore W2159392324C160268369 @default.
• W2159392324 hasConceptScore W2159392324C169760540 @default.
• W2159392324 hasConceptScore W2159392324C169900460 @default.
• W2159392324 hasConceptScore W2159392324C170493617 @default.
• W2159392324 hasConceptScore W2159392324C181199279 @default.
• W2159392324 hasConceptScore W2159392324C185592680 @default.

• next